- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting loss of heterozygosity for cancer-specific immunotherapy
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 118, Issue 12, Pages e2022410118
Publisher
Proceedings of the National Academy of Sciences
Online
2021-03-18
DOI
10.1073/pnas.2022410118
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The therapeutic landscape for cells engineered with chimeric antigen receptors
- (2020) Matthew MacKay et al. NATURE BIOTECHNOLOGY
- Assessing aneuploidy with repetitive element sequencing
- (2020) Christopher Douville et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients
- (2020) J.H. Shim et al. ANNALS OF ONCOLOGY
- T cell-engaging therapies — BiTEs and beyond
- (2020) Maria-Elisabeth Goebeler et al. Nature Reviews Clinical Oncology
- Cancer cell therapies: the clinical trial landscape
- (2020) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
- (2020) Veronica Rendo et al. Nature Communications
- Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities
- (2020) Caitlin A. Nichols et al. Nature Communications
- Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
- (2020) Sebastian P. Haen et al. Nature Reviews Clinical Oncology
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen
- (2020) Daichao Wu et al. Nature Communications
- Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
- (2020) Vid Leko et al. CANCER CELL
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
- (2020) Kevin R. Parker et al. CELL
- Engineered T cells directed at tumors with defined allelic loss
- (2020) Agnes E. Hamburger et al. MOLECULAR IMMUNOLOGY
- Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
- (2019) Winifred Lo et al. Cancer Immunology Research
- Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
- (2019) Shivani Srivastava et al. CANCER CELL
- Clinical lessons learned from the first leg of the CAR T cell journey
- (2019) Robbie G. Majzner et al. NATURE MEDICINE
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- Somatic Mutations and Loss of Heterozygosity of HLA Genes Are Frequently Occurred and Tightly Associated with Poor Prognosis in Adult T Cell Leukemia-Lymphoma
- (2019) Keita Tamaki et al. BLOOD
- An engineered antibody fragment targeting mutant β-catenin via major histocompatibility complex I neoantigen presentation
- (2019) Michelle S. Miller et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools
- (2019) Faviel F Gonzalez-Galarza et al. NUCLEIC ACIDS RESEARCH
- Genomic and immune profiling of pre-invasive lung adenocarcinoma
- (2019) Haiquan Chen et al. Nature Communications
- Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency
- (2019) David N. Nguyen et al. NATURE BIOTECHNOLOGY
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs)
- (2018) Christopher Douville et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15
- (2018) María A. Garrido et al. IMMUNOGENETICS
- Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
- (2018) Elena J. Orlando et al. NATURE MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Cancer Neoantigens
- (2018) Ton N. Schumacher et al. Annual Review of Immunology
- Putting the Immunologic Brakes on Cancer
- (2018) Jedd Wolchok CELL
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients
- (2018) Paola Montes et al. Oncotarget
- Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
- (2018) Keisuke Watanabe et al. Frontiers in Immunology
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm
- (2017) David T. Teachey et al. Nature Reviews Clinical Oncology
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector
- (2017) Ziqing Liu et al. Scientific Reports
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes
- (2015) Andrew D. Skora et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Immunogenicity of somatic mutations in human gastrointestinal cancers
- (2015) E. Tran et al. SCIENCE
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- The IPD and IMGT/HLA database: allele variant databases
- (2014) James Robinson et al. NUCLEIC ACIDS RESEARCH
- Lessons from the Cancer Genome
- (2013) Levi A. Garraway et al. CELL
- LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
- (2013) J. T. Yeung et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Pan-cancer patterns of somatic copy number alteration
- (2013) Travis I Zack et al. NATURE GENETICS
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions
- (2012) W. Xue et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential
- (2012) N. L. Solimini et al. SCIENCE
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors
- (2010) Isabel Maleno et al. IMMUNOGENETICS
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
- (2010) Maria R Parkhurst et al. MOLECULAR THERAPY
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A
- (2009) O R F Mook et al. CANCER GENE THERAPY
- Class I HLA Folding and Antigen Presentation in 2-Microglobulin-Defective Daudi Cells
- (2009) A. Martayan et al. JOURNAL OF IMMUNOLOGY
- Concerning the Origin of Malignant Tumours by Theodor Boveri. Translated and annotated by Henry Harris
- (2007) T. Boveri JOURNAL OF CELL SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started